Tempest Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Tempest Therapeutics, Inc. (TPST) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of -$117.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was -$117.00K, a 110.71% decline year-over-year.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $226.00K, a 83.73% decline year-over-year.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $61.00K, a 95.43% decline year-over-year.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $1.09M, a 17.27% decline year-over-year.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $3.12M, a 41.20% decline from fiscal 2024.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $5.30M, a 108.29% increase from fiscal 2023.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $2.55M, a 63.10% increase from fiscal 2022.
- Tempest Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $1.56M, a 41.27% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$117.00K 10-Q · filed 2026-08-13 | $109.00K derived: sum of 2 quarters · filed 2026-08-13 | |||||
| 2026-03-31 | $226.00K 10-Q · filed 2026-08-13 | ||||||
| 2025-12-31 | $3.12M 10-K · filed 2026-03-30 | ||||||
| 2025-09-30 | $61.00K 10-Q · filed 2025-11-05 | $1.15M derived: sum of 2 quarters · filed 2026-08-13 | $2.54M derived: sum of 3 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.09M 10-Q · filed 2026-08-13 | $2.48M derived: sum of 2 quarters · filed 2026-08-13 | |||||
| 2025-03-31 | $1.39M 10-Q · filed 2026-08-13 | ||||||
| 2024-12-31 | $5.30M 10-K · filed 2026-03-30 | ||||||
| 2024-09-30 | $1.33M 10-Q · filed 2025-11-05 | $2.65M derived: sum of 2 quarters · filed 2025-11-05 | $3.97M derived: sum of 3 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $1.32M 10-Q · filed 2025-11-05 | $2.64M derived: sum of 2 quarters · filed 2025-11-05 | |||||
| 2024-03-31 | $1.32M 10-Q · filed 2025-11-05 | ||||||
| 2023-12-31 | $2.55M 10-K · filed 2025-03-27 | ||||||
| 2023-09-30 | $563.00K 10-Q · filed 2024-11-12 | $1.00M derived: sum of 2 quarters · filed 2024-11-12 | $1.45M derived: sum of 3 quarters · filed 2024-11-12 | $2.68M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $440.00K 10-Q · filed 2024-11-12 | $886.00K derived: sum of 2 quarters · filed 2024-11-12 | $2.12M derived: sum of 3 quarters · filed 2024-11-12 | $2.56M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $446.00K 10-Q · filed 2024-11-12 | $1.68M derived: sum of 2 quarters · filed 2024-11-12 | $2.12M derived: sum of 3 quarters · filed 2024-11-12 | $2.48M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2022-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.67M derived: sum of 2 quarters · filed 2024-03-19 | $2.04M derived: sum of 3 quarters · filed 2024-03-19 | $1.56M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $438.00K 10-Q · filed 2023-11-08 | $805.00K derived: sum of 2 quarters · filed 2023-11-08 | $328.00K 10-Q · filed 2022-11-08 | $1.41M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $367.00K 10-Q · filed 2023-11-08 | $695.00K 10-Q · filed 2022-08-15 | $973.00K derived: sum of 3 quarters · filed 2023-11-08 | $1.27M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-03-31 | $328.00K 10-Q · filed 2023-11-08 | $606.00K derived: sum of 2 quarters · filed 2023-11-08 | $902.00K derived: sum of 3 quarters · filed 2023-11-08 | $1.31M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2021-12-31 | $278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $574.00K derived: sum of 2 quarters · filed 2023-03-22 | $985.00K derived: sum of 3 quarters · filed 2023-03-22 | $1.10M 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $296.00K 10-Q · filed 2022-11-08 | $707.00K derived: sum of 2 quarters · filed 2022-11-08 | $827.00K 10-Q · filed 2021-11-10 | $958.00K derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $411.00K 10-Q · filed 2022-11-08 | $531.00K 10-Q · filed 2022-08-15 | $662.00K derived: sum of 3 quarters · filed 2022-11-08 | $754.00K derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-03-31 | $120.00K 10-Q · filed 2022-11-08 | $380.00K 10-Q · filed 2021-05-13 | $251.00K derived: sum of 2 quarters · filed 2022-11-08 | $343.00K derived: sum of 3 quarters · filed 2022-11-08 | $570.00K derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2020-12-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $223.00K derived: sum of 2 quarters · filed 2022-03-29 | $450.00K derived: sum of 3 quarters · filed 2022-03-29 | $453.00K 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $92.00K 10-Q · filed 2021-11-10 | $1.09M 10-Q · filed 2020-11-09 | $319.00K derived: sum of 2 quarters · filed 2021-11-10 | $322.00K 10-Q · filed 2021-11-10 | $3.15M 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | $227.00K 10-Q · filed 2021-08-12 | $980.00K 10-Q · filed 2020-08-10 | $230.00K 10-Q · filed 2021-08-12 | $2.06M 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $1.08M 10-Q · filed 2021-05-13 | ||||||
| 2019-09-30 | $1.20M 10-Q · filed 2020-11-09 | $2.19M derived: sum of 2 quarters · filed 2020-11-09 | $3.13M 10-Q · filed 2020-11-09 | $3.80M derived: sum of 4 quarters · filed 2020-11-09 | |||
| 2019-06-30 | $995.00K 10-Q · filed 2020-08-10 | $1.93M 10-Q · filed 2020-08-10 | $2.60M derived: sum of 3 quarters · filed 2020-08-10 | $3.02M derived: sum of 4 quarters · filed 2020-08-10 | |||
| 2019-03-31 | $939.00K 10-Q · filed 2020-05-08 | $1.61M derived: sum of 2 quarters · filed 2020-05-08 | $2.03M derived: sum of 3 quarters · filed 2020-05-08 | $2.19M derived: sum of 4 quarters · filed 2020-05-08 | |||
| 2018-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.09M derived: sum of 2 quarters · filed 2019-11-13 | $1.25M derived: sum of 3 quarters · filed 2019-11-13 | $1.43M 10-K · filed 2019-04-01 | |||
| 2018-09-30 | $423.00K 10-Q · filed 2019-11-13 | $582.00K derived: sum of 2 quarters · filed 2019-11-13 | $759.00K 10-Q · filed 2019-11-13 | ||||
| 2018-06-30 | $159.00K 10-Q · filed 2019-08-12 | $336.00K 10-Q · filed 2019-08-12 | |||||
| 2018-03-31 | $177.00K 10-Q · filed 2019-05-15 | ||||||
| 2017-12-31 | $762.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |